CAN-FITE BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.7 ILa | 0.00% |
|
0.00% | +3.85% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 900K 335M | Sales 2025 * | 900K 335M | Capitalization | 10.85M 4.03B |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -2.6B | Net income 2025 * | -8M -2.97B | EV / Sales 2024 * | 12.1 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 12.1 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Can-Fite BioPharma Ltd.
More press releases
| 1 week | +3.85% | ||
| Current month | +3.85% | ||
| 1 month | -6.90% | ||
| Current year | +3.85% |
1 week
2.60
3.00
1 month
2.503.00
Current year
2.503.00
1 year
2.404.10
3 years
2.1031.10
5 years
2.1095.40
10 years
2.101 163.00
| Managers | Title | Age | Since |
|---|---|---|---|
Motti Farbstein
CEO | Chief Executive Officer | 59 | 03-07-31 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Abraham Sartani
BRD | Director/Board Member | 76 | 00-12-31 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-12 | 2.7 | 0.00% | 4 474 855 |
| 24-05-09 | 2.7 | 0.00% | 45,196,920 |
| 24-05-08 | 2.7 | 0.00% | 1,418,154 |
| 24-05-07 | 2.7 | -3.57% | 6,474,288 |
| 24-05-06 | 2.8 | +3.70% | 11,859,530 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 09, 2024 at 10:24 am EDT
More quotes
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.027
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.85% | 10.85M | |
| -2.61% | 89.08B | |
| +3.55% | 40.9B | |
| -14.40% | 32.25B | |
| +55.89% | 25.14B | |
| -15.96% | 15.39B | |
| -15.50% | 11.91B | |
| -41.29% | 11.89B | |
| -11.75% | 11.64B | |
| +7.87% | 9.03B |
- Stock Market
- Equities
- CANF Stock